Menopause hair loss system shows trial promise

Menopause hair loss trial data showed what the company called clinically meaningful regrowth from a scalp system in a phase II study of menopausal women.

The four-month independent trial evaluated Prevention and Treatment Serums in 43 menopausal-aged women with androgenetic alopecia.

Androgenetic alopecia is a common form of hair thinning.

The trial was announced by dermatologist-founded brand KilgourMD.

Dr James Kilgour, board-certified dermatologist, founder and chief executive of KilgourMD, said: “Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning.

“This study validates not only the performance of the KilgourMD System, but also the importance of designing and testing solutions specifically for this population.

“These results represent a meaningful step forward in how menopausal hair loss is treated.”

Unlike many studies in this category, eligibility required a clinically significant level of hair loss, and outcomes were objective and dermatologist-evaluated rather than consumer perception surveys.

By day 120, the company said 53 per cent of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a clinical scale used to rate the severity of female hair loss.

This threshold is considered by dermatologists to represent a meaningful visual change. A further 26 per cent showed a full one-grade improvement.

KilgourMD said this level of improvement is comparable to, and in some cases exceeds, results typically reported after six to 12 months of conventional pharmaceutical therapies such as minoxidil or finasteride.

Across the full study population, participants experienced an average 11.1 per cent improvement in Ludwig score within four months, the company said.

The trial also reported a 60 per cent reduction in hair shedding by month four, measured through standardised combing and washing assessments.

Reductions were seen as early as day 45, when more than 95 per cent of participants showed a decrease from baseline in terminal hair shedding count, measured by standardised hair washing studies in the lab.

Regrowth outcomes were graded by two independent board-certified dermatologists, with high-resolution imaging used to confirm visible improvements in hair density and scalp coverage over time.

More than 80 per cent of participants reported noticeable improvements in hair density, health and overall appearance by the end of the study.

The full results are currently undergoing peer review and are expected to be published later this year.